Fig. 2

Characterization of CD80 expression in AOM-induced colon dysplasia. Mice were injected with AOM i.p. at a dose of 10 mg/kg body weight and sacrificed 16 weeks after AOM injection (n = 15). (a) Representative immunohistochemical staining for CD80 of the colon from AOM treated mice exhibiting CD80+ cells in the normal (N) and dysplastic (D) epithelium. (b) Representative flow cytometry plots and frequency of CEC isolated from untreated (n = 13) and AOM treated mice (n = 15) expressing CD80. (c) Scheme for the experimental course of the colon carcinogenesis model in WT and CD80 KO mice and for the administration of neutralizing antibodies in WT mice. (d) Extension of dysplasia in AOM-treated WT mice subjected to administration of IgG, anti-CD80 antibodies (200 μg/mouse) and in AOM-treated CD80 KO mice. (n = 7–15 mice per group). (e) Representative flow cytometry plots and frequency of CD107a + T lymphocytes isolated from colon mucosa of AOM-treated WT mice subjected to administration of IgG, anti-CD80 antibodies (200 μg/mouse) and in AOM-treated CD80 KO mice (n = 7–15 mice per group). Data are presented as mean ± S.E.M. **P < 0.01 *** P < 0.001 by unpaired, two-tailed Student’s t-test